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Abstract
Purpose:  To  evaluate  the  risk  of  low-risk  prostate  cancer  or  prostate  cancer  that  may  bene-
ﬁt from  surveillance  in  patients  with  a  PSA  level  less  than  10  ng/ml,  a  normal  digital  rectal
examination  (DRE)  and  a  transrectal  power  Doppler  sonography  (PDS)  without  anomaly.
Patients  and  methods:  Two  hundred  and  forty-three  consecutive  patients  with  a  PSA  level  less
than 10  ng/ml  and  a  DRE  without  anomaly  had  PDS-guided  biopsies:  12  to  15  samples  were
systematically  taken  and  echo-guided  in  the  suspect  areas.  The  PDS  results  were  rated  from
1 to  4:  1:  normal,  2:  slightly  hypoechogenic  avascular  area  in  which  the  hypo-echogenicity
disappears  after  compression  by  probe,  3:  hypoechogenic  avascular  area,  4:  hypoechogenic
vascularised  area  with  power  Doppler  sonography.  Patients  rated  3  or  4  were  considered  to  be
pathological.  D’Amico’s  criteria  were  used  to  assess  the  risk  of  a  biological  recurrence  after
treatment and  those  of  Dall’Era  were  used  to  select  the  patients  that  could  beneﬁt  from  active
surveillance  (AS).  The  PDS  was  considered  to  be  a  true  positive  if  at  least  one  biopsy  was  positive
in the  same  sextant  as  the  suspect  image.
Results:  In  a  prospective  manner,  106  cancers  were  diagnosed  that  could  be  qualiﬁed  as  low-risk
in 84%  of  the  cases  (89%  with  a  normal  PDS  and  79%  with  an  abnormal  PDS).  Sixty-nine  percent
of the  cases  could  be  subject  to  AS  (86%  of  the  normal  PDS  cases  and  47%  of  the  abnormal  PDS
cases; P  <  0.001).  The  PDS  was  normal  in  159  of  the  243  patients  (65%).  With  a  normal  PDS,
there was  a  96%  probability  of  not  having  a  high-risk  cancer.  With  an  abnormal  PDS,  at  least  one
biopsy was  positive  in  57%  of  the  cases  and  the  probability  of  having  a  signiﬁcant  cancer  was
30% according  to  the  Dall’Era  criteria.  A  signiﬁcant  reduction  was  noted  with  a  normal  PDS,  to
36% and  5%,  respectively  (VPN  =  95%)  (P  =  0.015).
Conclusion:  A  normal  PDS  in  patients  presenting  a  PSA  level  less  than  10  ng/ml  and  a  DRE  without
anomaly may  be  used  to  put  off
well as  the  risks  of  overtreatmen
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The  limited  beneﬁts-risk  ratio  and  the  overtreatment
induced  by  the  screening  of  prostate  cancer  make  it  nec-
essary  to  better  select  candidate  patients  for  a  prostate
biopsy  with  the  search  for  more  individual  characteristics
that  help  differentiate  patients  with  aggressive  lesions  from
those  with  indolent  lesions  [1].
The  screening  is  currently  based  on  a  consensus  including
the  age  of  the  patient  (50  years),  a  clinical  examination  and
an  assay  of  the  PSA  level  for  which  the  upper  limit  is  set
at  4  ng/ml  [2].  However,  some  aggressive  cancers  are  below
this  level  [3].
Imaging  may  provide  a  more  personalised  approach  to  the
risk  of  having  an  aggressive  tumour  [4—7].
The value  of  sonography  combined  with  color  Doppler
sonography  (CDS)  and  power  Doppler  sonography  (PDS)  in
the  detection  of  prostate  cancer  has  given  rise  to  a  great
many  evaluations.  Cornud  et  al.  calculated  that  the  risk
of  a  positive  biopsy  was  11%  with  a  normal  digital  rec-
tal  examination  (DRE),  a  PSA  level  less  than  10  ng/ml
and  a  normal  CDS  and  that  the  CDS  may  be  of  use  to
distinguish  avascular  low-risk  tumours  from  hypervascular
high-risk  tumours  [8,9]. The  increasing  use  of  individual
screening  and  the  increased  number  of  biopsies  has  led
to  the  early  detection  of  increasingly  small  lesions.  In
view  of  these  small  lesions,  the  value  of  the  PDS  was  low
since  a  signiﬁcant  number  of  sometimes  little  differenti-
ated  cancers  were  non-palpable  and  not  visible  [10,11].
Sometimes  large,  anterior  cancers  as  well  as  those  of
the  transition  area  were  not  detectable  in  the  sonogra-
phy  examination.  The  only  known  value  of  the  PDS  was
that  of  directing  the  biopsies  when  a  suspect  area  was
detected.
Among  the  small  lesions  thereby  detected,  some  well-
differentiated  lesions  may  be  qualiﬁed  as  latent,  painless
or  non-signiﬁcant.  They  are  at  the  origin  of  an  overdiag-
nosis  involving  40%  of  the  patients  treated  [12]. The  risk
of  an  overdiagnosis  and  overtreatment  of  a  lesion  has  until
now  been  underestimated  and  the  active  surveillance  proto-
cols  proposed  are  probably  not  adapted  to  the  psychological
proﬁle  of  each  patient.
Technical  progress  in  Doppler  sonography  and  a  better
understanding  of  its  value  and  limits  may  help  better  inte-
grate  them  in  a  diagnostic  approach  [13,14].
The  purpose  of  this  paper  is  to  assess  the  probability
of  not  having  an  evolving  high-risk  lesion  in  prostate  biop-
sies  in  patients  with  a  normal  DRE,  a  PSA  level  between  4
and  10  ng/ml  and  a  prostatic  transrectal  sonography  with  a
normal  PDS  examination.
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Table  1  Study  on  413  consecutive  patients  undergoing  biop
according  to  their  PSA  level,  PDS  results  and  the  risks  of  biolo
active  surveillance  (Dall’Era)  [16,18].
Patients
biopsied
Positive  patients
after  biopsies
Po
af
PSA  >  10  ng/ml  114  62  (54%)  4
PSA  <  10  ng/ml  299  139  (46%)  7
PSA  <  10  ng/ml  T1c 243  106  (43%)  4
Total  413  201  (48%)  1261
aterials and methods
he patients
our  hundred  and  thirteen  patients  (49  to  87  years,  mean
ge:  64  years  and  median  age:  66  years),  between  Septem-
er  2009  and  December  2011  underwent  a  series  of  biopsies.
wo  hundred  and  ninety-nine  presented  a  PSA  level  between
 ng/ml  and  10  ng/ml.  The  digital  rectal  examination  was
ormal  in  243  of  them.  Hundred  and  six  non-palpable
ancers  were  diagnosed  in  the  biopsies  and  classiﬁed  as
T1c  in  the  cTNM  classiﬁcation  for  prostate  cancer  (mean
SA:  6.2  ng/ml,  median:  7  ng/ml,  from  4.01  to  10  ng/ml)
Table  1).
onography technique and power Doppler
ode
his  study  was  carried  out  with  Philips  HDI  5000  power
oppler  sonography  instruments  (Philips  Ultrasound,  Both-
ll,  WA,  USA)  coupled  with  a  C  9-5  ICT  endocavity  probe  and
oshiba  Aplio  MX  (Toshiba  MS,  Nasu,  Japan)  coupled  with  a
iplane  PVT-770RT  endocavity  probe  (5—10  mhz).  As  a  com-
lement  to  the  endorectal  sonography,  an  exploration  with
 power  Doppler  was  carried  out  in  all  patients.  The  Doppler
ncrease  was  optimised  in  each  patient  so  that  there  was  no
ackground  noise  at  about  80%.  We  privileged  a  low  PRF  that
as  adjusted  to  500  Hz  in  standard  value:  the  ﬁltration  and
ersistence  were  pre-set  at  their  maximum  level  in  order  to
imit  the  movement  artefacts.
A  weak  compression  with  the  end  of  the  probe  was  sys-
ematically  carried  out  in  case  of  a  hypoechogenic  area  in
he  search  for  a  modiﬁcation  of  its  echostructure.  The  mean
ime  for  a  Doppler  sonography  of  the  prostate  was  about
5  minutes.
ltrasound semiology and power Doppler [13]
n  B  mode,  the  peripheral  area  was  in  the  normal  state
omogenous  and  more  echogenic  than  the  transition  area.
he  suspect  echostructure  anomalies  in  the  peripheral
rostate  area  may  be  qualiﬁed  as  hypoechogenic,  weakly
ypoechogenic  or  subtle,  heterogenic.  The  power  Doppler
ode  searched  for  the  presence  of  intralesional  vessels  in  auspect  lesion  in  the  mode  B  sonography.  A  visible  lesion  in
 mode  was  said  to  be  hypervascularised  if  it  included  one
r  several  vessels.  The  lesion  was  qualiﬁed  as  focal  if  it  was
nder  5 mm.  However,  this  lesion  was  qualiﬁed  as  nodular
sy  after  power  Doppler  sonography  (PDS)  and  classiﬁed
gical  recurrence  (D’Amico)  or  the  possible  indication  for
sitive  patients
ter  EDP
Low-risk  CaP
according  to
d’Amico
CaP  that  may
beneﬁt  from  SA
(DallEra)
3  0  0
9  94  82
8  90  (84%)  73  (69%)
2  94  82
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f  it  was  over  5  mm  and  conﬁned  to  a  single  sextant,  com-
rising  vessels  remaining  strictly  intralesional.  If  the  zone
ypoechogenic  area  involved  three  sextants  or  more  and/or
f  the  vessels  extended  beyond  the  hypoechogenic  area,  the
esion  was  qualiﬁed  as  inﬁltrating.  If  the  lesion  was  nodu-
ar  or  focal  and  associated  with  outer  seats  without  real
ontiguity,  the  lesion  was  qualiﬁed  as  multifocal.
The  PDS  results  were  rated  from  1  to  4:  1:  normal,  2:
lightly  hypoechogenic  avascular  lesion  in  which  the  hypo-
chogenicity  disappears  after  slight  compression  with  the
robe  (Fig.  1),  3:  hypoechogenic  avascular  lesion  (Fig.  2),
:  weakly  hypoechogenic  hypervascularised  lesion  (Fig.  3)
nd  hypervascularised  heterogenous  or  hypervascularised
ypoechogenic  lesion  (Fig.  4).  Classes  3  and  4  were  con-
idered  to  be  pathological.
iopsies
his  study  was  prospective  and  was  declared  to  the  CNIL.
ach  patient  included  in  the  series  received  an  informa-
ion  form  that  was  drawn  up  by  the  French  Association  of
rology  (AFU)  [15]. Each  patient  beneﬁted  from  a  Doppler
onography  examination  before  the  biopsies.  In  case  of  a
isible  lesion,  the  location  was  determined  by  sextant  and
T
l
t
igure 1. Class 2: weakly hypoechogenic peripheral prostate without v
ompression: PSA: 6.2 ng/ml, negative biopsies.
igure 2. Class 3: weakly hypoechogenic and avascular peripheral pros
rostate 45 g, clinical examination normal, PSA: 7 ng/ml, Gleason score J.-L.  Sauvain  et  al.
ndicated  in  the  information  sheet  appended  to  the  sam-
les  sent  to  the  anatomopathologist.  The  radiologist  carried
ut  the  echo-guidance  and  oriented  the  biopsies  performed
y  the  urologist  surgeon.  Two  urologist  surgeons  and  four
xperienced  radiologists  participated  in  this  study.  Twelve
amples  were  systematically  taken,  according  to  the  rec-
mmendations  for  good  biopsy  practices  proposed  by  the
FU  [15]. One  to  three  additional  samples  were  sometimes
dded  in  case  of  suspect  lesions  in  the  PDS  located  outside
f  the  path  of  the  systematic  biopsies.
All  non-palpable  cancers  (clinical  stage:  cT1c)  with  a
SA  level  less  than  10  ng/ml  were  classiﬁed  according  to
’Amico’s  classiﬁcation  that  introduced  three  levels  of  risk
f  biological  recurrence  after  treatment  (low,  intermediate
nd  high)  and  Dall’Era’s  criteria  [18]  to  assess  the  possibility
f  active  surveillance  (Table  2)  [16,17].  These  criteria  were
onsidered  as  the  best  evaluated  and  appear  to  be  the  most
onsensual  in  the  European  community  [19].
tatistical analysishe  imaging  results  were  correlated  with  the  anatomopatho-
ogical  examinations  of  the  biopsies.  A  result  was  declared
o  be  a  true  positive  if  at  least  one  biopsy  was  positive  in  the
ascular anomaly, the hypoechogenic appearance disappears under
tate, the hypoechogenic appearance continues after compression:
6 (3 + 3).
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Figure 3. Class 4: weakly hypoechogenic and hypervascular peripheral prostate: Prostate 120 g, clinical examination normal, PSA:
9.6 ng/ml, Gleason score 7 (3 + 4).
Figure 4. Class 4: non-palpable hypoechogenic and hyervascular lesions: a: PSA: 4.5 ng/ml, Gleason score 7 (4 + 3): one positive biopsy;
luded
E
tb: PSA: 7.4 ng/ml, Gleason score 6 (3 + 3): two positive biopsies inc
(3 + 3): three positive biopsies.
same  sextant  as  a  class  3  or  4  image.  A  result  was  declared  to
be  a  true  negative  if  no  biopsy  was  found  to  be  positive  dur-
ing  an  examination  without  a  visible  lesion  (class  1  and  2).
The  sensitivity,  speciﬁcity,  positive  and  negative  predictive
values  (NPV),  as  well  as  the  accuracy  of  the  diagnosis  of  can-
cer  were  calculated  and  the  signiﬁcance  assessed  with  the
Chi2 test  (P  <  0.05).  Mac  Nemar’s  test  was  used  when  both
methods  were  compared  (threshold  of  signiﬁcance:  <  0.05).
R
T
o on invaded greater than 50%; c: PSA: 6.2 ng/ml, Gleason score 6
PI  info  6  programmes  were  used  for  the  statistical  calcula-
ions.esults
wo  hundred  and  forty-three  (59%)  of  all  patients  screened  in
ur  study  had  a PSA  level  less  than  10  ng/ml  without  palpable
64  J.-L.  Sauvain  et  al.
Table  2  Selection  criteria  for  evolving  low-risk  prostate
cancers  according  to  D’Amico  and  Dall’Era.
D’Amico  et  al.  [17] PSA  level  <  10  ng/ml
No  grade  4  or  5
Clinical  stage  not  exceeding  T2a
Dall’Era  et  al.  [16]
(criteria  most
often  used)
Clinical  stage  not  exceeding  T2a
No  grade  4  or  5
PSA  level  <  10  ng/ml
Kinetics  of  the  PSA  level  stable
<  33%  positive  biopsies
<  50%  cancer  by  biopsy
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Figure 5. Hundred and six patients with cT1c cancer: results of
the power Doppler sonography (PDS) according to the D’Amico risk
criteria and active surveillance (AS) by Dall’Era.
Table  4 Probability  of  having  a  positive  biopsy  in  case
of  normal  power  Doppler  sonography  (PDS)  (PDS−) and
abnormal  PDS  (PDS+)  according  to  the  D’Amico  and
Dall’Era  criteria.
PDS+  (%)  PDS− (%)  P
Biopsy  risk+  57  36  0.001
Low  risk
D’Amico  42  33  0.16
Dall’Era  27  31  0.57
High  risk
D’Amico  12  4  0.015
D
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(esion:  106  patients  presented  a  cancer  (43%  of  the  cases),
ncluding  58  with  a  normal  PDS  (Table  1).
These  106  diagnosed  cT1c  cancers  may  be  qualiﬁed  as
ow-risk  in  84%  of  the  cases  (89%  with  a  normal  PDS  and  79%
ith  an  abnormal  PDS).  Sixty-nine  percent  of  the  cases  may
eneﬁt  from  AS  (86%  of  the  normal  PDS  cases  and  47%  of  the
bnormal  PDS  cases;  P  <  0.001).
The  diagnostic  accuracy  of  the  PDS  was  65%  when  it
onsisted  of  the  diagnosis  of  all  of  the  T1c  cancers.  It  was
3%  in  the  cancers  with  an  intermediate  or  high  risk  accord-
ng  to  D’Amico  and  82%  in  the  diagnosis  of  signiﬁcant  cancers
hat  may  not  beneﬁt  from  AS  according  to  Dall’Era  (P  <  0.01)
Table  3,  Fig.  5).
The  58  negative  PDS  cancers  account  for  55%  of  all  of  the
T1c  cancers  and  42%  of  all  of  the  cancers  where  the  PSA
evel  did  not  exceed  10  ng/ml.
Among  the  243  patients  tested,  the  PDS  was  normal  in
59  (65%)  of  them.  With  a  normal  PDS,  the  probability  of
ot  having  a  cancer  with  a  high  risk  is  96%  (NPV).  With  an
bnormal  PDS,  the  probability  of  having  a  positive  biopsy
as  57%  and  the  probability  of  having  a  signiﬁcant  cancer
as  30%  according  to  the  Dall’Era  criteria.  With  a  normal
DS,  these  probabilities  decrease  in  a  signiﬁcant  manner  to
6%  and  5%  respectively  (NPV  =  95%)  (P  =  0.015)  (Table  4).Table  3  Diagnostic  value  of  the  power  Doppler  sonog-
raphy  (PDS)  in  243  consecutive  patients  presenting  a  PSA
level  <  10  ng/ml  in  cT1c  cancers,  cT1c  cancers  with  a  high
risk  of  biological  recurrence  according  to  D’Amico  and
in  the  cT1c  cancers  that  may  not  beneﬁt  from  active
surveillance  according  to  Dall’Era.
T1c D’Amico  Dall’Era
VN  101  153  151
VP 48 48  48
FN 58 6 8
FP 36  36  36
Sensitivity  (%) 45 89  86
Speciﬁcity  (%) 74 81 81
VPP  (%)  57  57  57
VPN  (%)  63  96  95
Accuracy  (%)  65  83  82
p
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tD’Allera  30  5  0.015
iscussion
he  negative  predictive  value  of  the  PDS  can  differenti-
te  most  low-risk  lesions  from  intermediate  and  high-risk
esions.
Several  studies  have  already  found  high  VPN  values
between  73  and  80%)  and  higher  than  those  observed  in  our
opulation  (63%)  (Table  3).  This  involves  all  patients  with  a
T1c  cancer,  independent  of  the  criteria  for  risk  of  evolution
6,10].
The  statistical  criteria  to  judge  the  gravity  of  a  prostate
ancer  are  multiple  but  difﬁcult  to  apply  individually.
The  screening  of  prostate  cancer  by  the  assay  of  the
SA  level  is  the  cause  of  an  overdiagnosis  [20,21].  The  ran-
omised  European  study  [22]  notes  that,  to  avoid  one  case
f  death  due  to  prostate  cancer,  it  is  necessary  to  screen
lmost  1410  men  considering  themselves  to  be  healthy  and
reat  48  patients  with  prostate  cancer.  The  annual  rate  of
ortality  of  low-risk  cancers  of  the  prostate  seems  to  remain
table  15  years  after  their  diagnosis  [23]  and  Sandblom  [24]
emonstrated  that,  after  a  survival  of  20  years,  the  differ-
nce  in  the  mortality  due  to  prostate  cancer  does  not  differ
etween  the  screened  group  and  the  reference  group.
The  overdiagnosis  concerns  40%  of  the  screened  patients
21]  (82  of  the  201  cancers  or  40.7%  of  the  patients  in  our
eries  after  the  biopsies  would  have  beneﬁted  from  active
urveillance)  (Table  1).  Without  a  non-invasive  diagnostic
ool,  the  risk  of  an  overdiagnosis  cannot  be  evaluated  before
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the  biopsies  are  carried  out.  Our  study  shows  that  the  PDS
can  assess  part  of  this  risk:  when  the  PDS  is  normal  in  the
243  patients  in  our  study  in  which  the  clinical  examination
is  normal  and  the  PSA  level  does  not  exceed  10  ng/ml,  the
probability  of  detecting  a  high-risk  lesion  in  the  biopsies  is
only  5%.  In  addition,  consideration  of  the  results  of  the  PDS
in  this  group  of  patients  may  put  off  or  even  cancel  a  great
many  useless  biopsies.
The  cT1  c  cancers  associate  low-risk  lesions  with  other
higher-risk  lesions.  By  selecting  the  patients  without  pal-
pable  lesion  and  in  whom  the  PSA  level  does  not  exceed
10  ng/ml,  we  have  two  of  the  three  conditions  included  in
D’Amico’s  group  of  low-risk  cancers.  Certain  studies  have
shown  a  correlation  between  the  grade  of  tumour  and  the
Doppler  sonograph  imaging  [4—7], although  this  correlation
has  never  been  validated.
In  our  study,  patients  with  a  PSA  level  ranging  from  4  to
10  ng/ml  and  a  normal  DRE  had  a  46%  risk  of  having  a  cancer
and  a  36%  risk  of  having  a  cancer  that  could  not  beneﬁt  from
AS:  with  a  normal  PDS,  these  risks  decrease  to  36%  and  5%
respectively  in  this  same  population.  Thompson  [3]  observed
that  10  to  25%  of  the  cancers  associated  with  a  PSA  level
ranging  from  0.6  to  4  ng/ml  had  a  Gleason  score  equal  to  or
higher  than  7.  This  risk  is  usually  accepted  in  the  individual
screening  strategy.
The  negative  predictive  value  of  the  PDS  may  signiﬁcantly
modify  the  risk  of  having  or  not  having  an  aggressive  lesion
and  may  weigh  the  statistical  risk  of  the  PSA  level.
The  negative  predictive  value  of  the  MRI  exceeds  90%
with  an  accuracy  of  98%  in  the  diagnosis  of  signiﬁcant  can-
cers  [25]. Independent  of  the  fact  that  its  high  sensitivity
also  favours  the  overdiagnosis  of  a  great  many  lesions  under
0.5  cc,  its  negative  predictive  value  in  the  diagnosis  of  high-
risk  cancers  is  not  much  higher  than  that  of  the  PDS  and  the
technique  is  much  more  complicated.  The  low  availability
of  the  machines  and  the  high  cost  of  the  examination  do  not
allow  for  its  systematic  use  before  the  biopsies.  The  MRI  may
play  a  role  when  the  kinetics  of  the  PSA  level  is  suspect  and
when  no  target  is  visible  in  the  PDS  examination.
Is  it  legitimate  to  delay  biopsies  when  an  indolent  lesion  is
suspected?  The  existence  of  latent  or  non-signiﬁcant  cancers
has  been  suspected  since  the  results  of  the  ﬁrst  series  were
published  after  autopsies  [26—28]. After  radical  prostatec-
tomy,  Epstein  [29]  and  Mc  Neal  [30]  considered  lesions  as
probably  indolent  when  the  volume  was  less  than  0.5  cc  and
accompanied  by  a  Gleason  score  less  than  7.
The  idea  of  non-signiﬁcant  lesions  based  on  the  results  of
biopsies  is  less  consensual  since  the  biopsies  underestimate
the  volume  of  the  tumour  and  cell  differentiation.
D’Amico’s  criteria  to  assess  the  risks  of  biological  recur-
rence  after  treatment  have  gained  a  wide  consensus  [16,17].
The  criteria  proposed  by  Dall’Era  (Table  2)  [18]  are  most
often  used  in  Europe  [19]  and  have  been  validated  over  long
periods  of  time.  Studies  on  cohorts  of  patients  with  clinically
localised  and  non-treated  prostate  cancer  have  shown  that
the  overall  survival  of  patients  with  a  Gleason  score  less  than
7  is  excellent  [17]. Therefore,  after  20  years,  the  speciﬁc
survival  of  the  patients  ranges  from  70  to  90%  [23,31,32].
The  data  from  the  ERSCP  group  was  presented  in  2005  [22]
with  even  less  constraining  criteria  (PSA  <  15  ng/ml  and  Glea-
son  score  <  8):  66%  of  the  patients  did  not  need  treatment
after  a  follow-up  of  6  years.  According  to  Dall’Era,  there
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s no  signiﬁcant  prognostic  difference  between  the  low-risk
atients  immediately  treated  and  those  that  beneﬁted  from
ctive  surveillance  before  surgery  [33].
Certain  authors  question  the  use  of  systematic  biopsies:
illiam  [1],  in  cases  where  the  PSA  greater  than  4  ng/ml
roposes  reducing  the  biopsy  indications  to  only  patients
ith  a  PSAD  greater  than  0.1  ng/ml/cc  or  with  an  abnormal
RE  and  in  case  of  a PSAD  less  than  0.1  ng/ml/cc  to  patients
ith  family  antecedents  or  obesity.
The  stability  of  the  PSA  level  is  an  element  that  is  rarely
aken  into  account  for  the  indication  of  a ﬁrst  series  of  biop-
ies.  It  is  one  of  the  criteria  for  active  surveillance.  This
riterion  is  not  evaluated  in  our  study.  Depending  on  whether
he  PSA  level  is  stable  or  decreasing  or,  on  the  contrary,
ncreasing  signiﬁcantly,  the  risk  with  this  diagnosis  proba-
ly  differs.  This  parameter  may  have  a  statistical  impact
ith  a  correlation  between  increasing  and  less  than  10  ng/ml
SA  and  abnormal  PDS  and  stable  PSA  and  normal  PDS.  In
his  case,  the  variable  PDS  would  not  be  independent.  If
emonstrated,  in  patients  with  a  PSA  level  not  exceeding
0  ng/ml,  a  normal  clinical  examination  and  a  normal  PDS,
tudy  of  the  PSA  kinetics  is  probably  justiﬁed  before  raising
he  indication  of  biopsies.
Our  study  presents  several  limits:  the  biopsies  underesti-
ate  the  volume  and  the  grade  of  the  lesions.  Twenty-three
o  35%  of  the  cancers  qualiﬁed  as  low-risk  present  an
xtraprostatic  extension  or  impairment  of  the  seminal  vesi-
les  after  radical  prostatectomy  [34]. The  grade  of  tumour
s  an  important  predictive  factor  in  the  recurrence  of  can-
er  after  treatment.  The  absence  of  biopsy  with  a  negative
DS  risks  underestimating  small  lesions  with  a  high  grade
r  certain  inﬁltrating  lesions  that  are  difﬁcult  to  identify
y  sonography.  However,  this  risk  is  present  in  patients
ith  a  PSA  level  under  4  ng/ml  although  it  is  consensually
ccepted,  as  we  reported  above,  since  Thompson’s  work  [3].
The  PDS  does  not  diagnose  transitional  or  anterior  lesions
f  the  prostate.  The  latter  are  usually  less  aggressive,  their
iagnostic  later  and  they  accompany  a  PSA  level  often
xceeding  10  ng/ml  [35].
Compression  with  the  end  of  the  probe  of  weakly
ypoechogenic  and  avascular  lesions  may  be  replaced  by
lastography.  This  is  currently  being  evaluated  and  may  help
mprove  the  speciﬁcity  and  negative  predictive  value  [36]  of
he  DRE-PDS  pair.  Sonography  is  an  operator-dependent  and
aterial-dependent  examination  and  the  clinical  examina-
ion  is  subjective.
Sonography  coupled  with  the  Doppler  examination
emains  an  examination  that  is  easily  accessible  and  cheap.
ts  performance  may  be  improved  by  the  rules  of  good
ractice  that  still  have  to  be  determined.
onclusion
wenty-eight  percent  of  all  cancers  diagnosed  in  our  series
ere  T1c  cancers  where  the  PSA  level  did  not  exceed
0  ng/ml  and  were  not  visible  in  the  PDS.  Eighty-nine  per-
ent  of  these  cancers  involved  a low-risk  of  biological
ecurrence  and  86%  of  the  cases  could  beneﬁt  from  active
urveillance  according  to  the  Dall’Era  criteria  after  the
iopsies.  Patients  with  a  PSA  level  not  exceeding  10  ng/ml
ithout  a  DRE  anomaly  and  with  a  negative  PDS  (35%  of  the
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ubjects  tested)  had  less  than  a  5%  risk  of  having  a  high-risk
ancer.  In  these  patients,  the  biopsies  probably  could  be  dif-
ered  and  carried  out  on  the  basis  of  arguments  other  than
nly  the  initial  assay  of  the  PSA  level  in  order  to  limit  the
umber  of  useless  biopsies  and  reduce  the  risks  of  overdiag-
osis.
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